Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13Market news · 9 Sep 2026
Tracking Cathie Wood: Added over 110,000 shares of gene-editing firm NTLA, while continuing to reduce holdings and optimize portfolio allocation.牛牛名人追蹤 · 14 Sep 2026
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $17Market news · 8 Aug 2026
CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49Market news · 8 Aug 2026
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9Market news · 7 Aug 2026
Evercore Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $24Market news · 7 Aug 2026
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25Market news · 7 Aug 2026
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29Market news · 15 Aug 2026
Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $15Market news · 10 Aug 2026
Wolfe Research Downgrades Intellia Therapeutics(NTLA.US) to Sell Rating, Announces Target Price $9Market news · 16 Jul 2026
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $19 to $49Market news · 16 Jun 2026
William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy RatingMarket news · 15 Jun 2026
TD Cowen Maintains Intellia Therapeutics(NTLA.US) With Buy RatingMarket news · 15 Jun 2026
J.P. Morgan Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Announces Target Price $8Market news · 14 May 2026
Discussion
No comments yet — be the first to weigh in on NTLA.
No comments yet — be the first to weigh in on NTLA.